Table I.
Frequency of various aberrant antigen expression and aberrant pattern abnormalities in patients with proven and suspected myelodysplastic syndrome (MDS)
| Aberrant expression pattern | Proven MDS (n=26) | Suspected MDS (n=18) | ||||
|---|---|---|---|---|---|---|
| Myeloblasts n (%) | Maturing granulocytes n (%) | Monocytes n (%) | Myeloblasts n (%) | Maturing granulocytes n (%) | Monocytes n (%) | |
| Aberrant expression of CD56 | 7 (26.9) | 13 (50) | 14 (53.8) | 0 | 4 (22) | 7 (38.8) |
| Aberrant expression of CD5 | 2 (7.6) | 1 (3.8) | 1 (3.8) | 1 (5.5) | 0 | 0 |
| Aberrant expression of CD7 | 1 (3.8) | 0 | 0 | 1 (5.5) | 1 (5.5) | 1 (5.5) |
| Asynchronous expression of CD34 | - | 1 (3.8) | 2 (7.6) | - | 0 | 0 |
| Decreased expression of CD10 | - | 7 (26.9) | - | - | 6 (33.3) | - |
| Increased expression of HLA-DR | - | 9 (34.6) | - | - | 4 (21.3) | - |
| Decreased expression of HLA-DR | - | - | 7 (26.9) | - | - | 1 (5.55) |
| Decreased expression of CD11b | - | - | 10 (38.4) | - | - | 5 (27.7) |
| Aberrant pattern of CD13/CD11b | - | 21 (80.7) | - | - | 6 (33.3) | - |
| Aberrant pattern of CD11b/CD16 | - | 18 (69.2) | 16 (61.5) | - | 5 (27.7) | 6 (33.3) |
| Aberrant pattern of CD13/CD16 | - | 18 (69.2) | - | - | 6 (33.3) | - |
| Aberrant pattern of HLA-DR/CD11b | - | 8 (30.7) | 14 (53.8) | - | 5 (27.7) | 4 (22.2) |